摘要
目的探讨慢性乙型肝炎/乙肝肝硬化长期治疗过程中阿德福韦酯(ADV)的肾毒性,为临床安全用药提供依据。方法监测2012年12月-2013年12月在陕西省人民医院传染科门诊服用ADV治疗的93例慢性乙型肝炎/乙肝肝硬化患者的血磷、肌酐水平。结果低血磷发生率为17.2%,服药时间长、年龄大、肝硬化者易发生低血磷。1例患者在ADV治疗期间出现低血磷并伴血清肌酐升高,病理检查示慢性肾间质炎、肾小球增生硬化。结论服用ADV期间需定期监测血磷、血清肌酐水平,尤其是肝硬化、年龄大、服用时间长者,必要时行肾穿刺病理检查。
Objective To investigate the nephrotoxicity of Adefovir dipivoxil（ ADV） during long-time treatment of hepatitis B and / or hepatic cirrhosis caused by hepatitis B. Methods Serum phosphorus and creatinine of 93 patients with chronic hepatitis B and / or hepatic cirrhosis during treatment of ADV from Dec. 2012 to Dec. 2013 in the Department of Infectious Disease,Shaanxi Provincial People＇s Hospital were monitored. Results The incidence of hypophosphatemia was 17. 2%. The longer medication duration,elderly and cirrhotic patients were more likely to have hypophosphatemia. One patient who had hypophosphatemia accompanied with increased creatinine and renal chronic interstitium inflammation and glomerular sclerosis was reported. Conclusion Patients treated with long-term ADV should have regular monitoring of serum phosphate and creatinine levels,especially longer medication duration,elderly and cirrhotic patients.
出处
《胃肠病学和肝病学杂志》
CAS
2015年第7期837-839,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
慢性乙型肝炎
低磷血症
阿德福韦酯
肌酐
肾毒性
Chronic hepatitis B
Hypophosphatemia
Adefovir dipivoxil
Creatinine
Nephrotoxicity
